Philips has announced FDA clearance of its MicroDose SI full-field digital mammography (FFDM) system. In addition to the capabilities of the original MicroDose approved in 2011, the company touts the SI model’s ability to do single-shot spectroscopy, yet that particular feature is not yet available in the U.S.
The MicroDose device use X-ray photon-counting detectors to perform breast tissue imaging at a considerably lower dose compared to traditional mammography. It is hoped the technology will improve the ability of radiologists to spot tumors within dense breast tissue.
As in existing Philips MicroDose systems, MicroDose SI uses unique digital photon-counting technology, which represents a paradigm shift in mammography by enabling clinicians to conduct exams using low radiation dose without compromising image quality. Philips has further advanced this unique technology with Single-Shot Spectral Imaging, which is built upon the fact that breast density is subject to different tissue types and materials that absorb X-rays at various energies. The technology powering the MicroDose SI uses this fundamental behavior of X-rays, allowing clinicians to see more than just a shadow in mammogram images by separating high and low energy X-ray within one single exposure.
Key advantages of MicroDose SI include:
High image quality at low X-ray dose (18 to 50 percent lower radiation dose than other digital mammography systems with an average dose reduction of 40 percent)
Short exam time – less than 5 minutes including image acquisition
Patient comfort with anatomically curved and warmed breast support
Ready for future Single-Shot Spectral Imaging applications
Product page: MicroDose Mammography SI